Dutch Life Sciences conference

👇 Check out this after movie from our exhibitor Eurofins BioPharma Product Testing Europe!

Today is a day for winners 🏆 ! We congratulate Sniper Therapeutics, the winner of the Venture Challenge Fall 2024. We celebrate the winner of the Investor Forum 2024 Stijn Heessen, Alder Therapeutics. We thank our speakers, Suzanne Spliethoff and our partners and exhibitors for making today an exciting event where the Dutch life science industry connected, met up again and shared lessons and experience here at CORPUS Congress Centre . And special thanks to our attendees, who help make this another great event for the Dutch Life Sciences. We look forward to seeing you again in 2025 on December 11! If you wish to be notified first when the early-bird tickets become available, sign up for our news update: https://lnkd.in/ek5k_T-c

We welcome our speakers and attendees to the 20th edition of the Dutch Life Sciences conference, today at CORPUS Congress Centre. Having started early this morning with the Investors Forum breakfast session, we are now gathering for the official opening with our chair Suzanne Spliethoff and Esther Peters, Director Leiden Bio Science Park. The first keynote talk will be delivered by Jolanda Crombach, Managing Director Moderna, who will discuss how Moderna has evolved from over 12 years of R&D and the success of its COVID-19 mRNA vaccine into a multi-product company at the forefront of innovation. The conference today is completely sold out! This means that the Dutch Life Sciences Conference 2024 is another great example of collaboration and growth for the Dutch life sciences community, made up from companies, investors and service providers who make up this first class life sciences and health community in the Netherlands. At the end of the day we will announce next year’s edition of the Dutch Life Sciences conference on December 11, 2025. If you are not in attendance today, make sure you note that date in your calendar for next year! Stay tuned and subscribe to our newsletter https://lnkd.in/ek5k_T-c #DutchLifeSciencesConference #DutchLifeSciences #LifeSciences #DLS2024 #DLS2025

12 promising start-ups getting ready to pitch at the Dutch Life Sciences conference Investors Forum tomorrow! The Investors forum offers an exciting opportunity for young companies looking for equity capital and/or partnerships. Many promising start-ups applied for this year's forum and following the recent presentation of their test pitches to the jury, 12 selected companies are getting ready to deliver their pitch during the Investors forum breakfast and lunch sessions tomorrow » https://lnkd.in/gSheCP2. The winner will also present the winning pitch in the plenary programme at DLSC and will be awarded a partnering ticket with a total value of EUR 2,500 and a half-day PwC Booster Session.    After winning the pitch competition at the DLSC Investors Forum 2023, last year's winner Predica Diagnostics BV made some great strides on their mission to improve the diagnosis, prognosis and treatment of cervical cancer, announcing their first product earlier this year. Winning the competition was not only great recognition, but also proved helpful to further develop their pitch and to demonstrate the value that Predica may hold for potential investors and partners. Read about how they used the PwC Booster Session in this article: https://lnkd.in/ew8Cuabn

Who will benefit from this year's PwC Booster session like Predica Diagnostics BV did? Check out the Investors Forum candidates at https://lnkd.in/gSheCP2 👇

🎉 Together with our partners, sponsors and exhibitors, we will celebrate the 20th anniversary of the Dutch Life Sciences conference on December 12 in CORPUS Congress Centre. We are pleased that the following companies and institutes will present their technology, service, product and collaborations on the exhibition floor. You can meet, mingle and make new contacts with future partners and customers. There will also be plenty of time to network throughout the day, during the breaks and the closing reception.   🎟️ Just a few tickets left so register now: https://lnkd.in/gDRMcDA 🤝 Meet with our partners and exhibitors: Health~Holland, Leiden Bio Science Park, Axon Lawyers, Johnson & Johnson Innovation, Pivot Park, Progress - Experts in Life Sciences, PwC Nederland, QAD, QbD Group, Thermo Fisher Scientific, V.O. Patents & Trademarks, hollandbio 3D-PharmXchange, ACROBiosystems, Advipro, Bio-Techne, Brightlabs BV, Broekbakema, BWT Nederland B.V., CONVAL group, eLabNext, Ellab - Validation & Monitoring Solutions, Eurofins, GenScript, Ignite Group Nederland, Kropman Contamination Control, KuiperCompagnons, Kuijpers, Rotterdam Square, Selvita, Tebubio, Vaisala and Yxion. #DutchLifeSciencesConference #DutchLifeSciences #LifeSciences #DLS2024

Looking forward to the pitches of these great Venture Challenge teams next week! 👇

The power of mRNA: transforming healthcare beyond COVID-19 Upcoming Thursday (December 12th) at the Dutch Life Sciences conference, Jolanda Crombach, Managing Director at Moderna Netherlands, will discuss how Moderna has evolved from over 12 years of R&D and the success of its COVID-19 mRNA vaccine into a multi-product company at the forefront of innovation. The foundation of Moderna is built on a key principle: if mRNA works as a medicine for one disease, it has the potential to work for many others. Jolanda will explain how mRNA technology —by instructing the body to create its own medicines— has the potential to address not only infectious diseases like COVID-19 and RSV but also cancer, rare diseases, and autoimmune disorders. Jolanda will provide a comprehensive overview of mRNA technology and its production process, illustrating how its rapid and flexible development capabilities are revolutionizing healthcare. She will also explain the pivotal role AI plays in driving innovation and efficiency across Moderna’s R&D and wider operations. Additionally, Jolanda will touch on incorporating new technologies into the Dutch healthcare system. Finally, she will showcase how Moderna’s pipeline and strategic collaborations, including the mRNA Access program, are shaping the future of healthcare and amplifying the impact of mRNA technology. For more information and registration: https://lnkd.in/dv8T5hH   #DutchLifeSciencesConference #DutchLifeSciences #LifeSciences #DLS2024

Join us on December 12, at the Dutch Life Sciences conference for a session about ´The road to IPO´ hosted by PwC. In line with the broader IPO market, activity in the pharmaceutical, biotech, and medtech industry has been subdued over the last few years. While there has been a recent uptick in activity driven by advancements in technology and decreasing interest rates, the IPO process remains challenging. To attract investors, life science leaders must not only deliver a clear equity story, but also ensure their organisation is public-company ready with a robust regulatory, corporate, and environmental governance framework. This session will be led by PwC IPO experts (Lena Takehana, CPA, Director, Capital Markets at PwC and Pepijn Holst, CFA, Manager, Capital Markets at PwC) who will be joined by a panel of life sciences executives (Louise Kooij, Chief Accounting Officer at NewAmsterdam Pharma Corporation and Sander Slootweg, Co-owner at Forbion) who recently navigated the IPO journey. Register now, to attend the 20th edition of the Dutch Life Sciences conference, December 12 at the Leiden Bio Science Park (CORPUS Congress Centre) >> https://lnkd.in/gDRMcDA Only a few tickets remain available! #DutchLifeSciencesConference #DutchLifeSciences #LifeSciences #DLS2024

Great to have you at the conference RIBOPRO! Looking forward to meeting you in Leiden on December 12.